PatientsVille.com Logo

Blood and Asasantin

PatientsVille

Blood Symptoms and Causes

Your Blood is made up of liquid and solids. The liquid part, called plasma, is made of water, salts, and protein. Over half of your Blood is plasma. The solid part of your Blood contains red Blood cells, white Blood cells, and platelets.

Red Blood cells (RBC) deliver oxygen from your lungs to your tissues and organs. White Blood cells (WBC) fight infection and are part of your immune system. Platelets help Blood to clot when you have a cut or wound. Bone marrow, the spongy material inside your bones, makes new Blood cells. Blood cells constantly die and your body makes new ones. Red Blood cells live about 120 days, and platelets live about 6 days. Some white Blood cells live less than a day, but others live much longer.

There are four Blood types: A, B, AB, or O. Also, Blood is either Rh-positive or Rh-negative. So if you have type A Blood, it's either A positive or A negative. Which type you are is important if you need a Blood transfusion. And your Rh factor could be important if you become pregnant - an incompatibility between your type and the baby's could create problems.

Blood tests such as Blood count tests help doctors check for certain diseases and conditions. They also help check the function of your organs and show how well treatments are working. Problems with your Blood may include bleeding disorders, excessive clotting and platelet disorders. If you lose too much Blood, you may need a transfusion.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for blood

blood treatment research studies

Asasantin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Asasantin Side Effects

Cerebrovascular Accident (15)
Renal Failure (7)
Gastric Ulcer (6)
Haemoglobin Decreased (6)
Rash Erythematous (5)
Angina Pectoris (4)
Transient Ischaemic Attack (4)
Gastrointestinal Haemorrhage (4)
Nausea (4)
Anaemia (4)
Pyrexia (3)
Haematemesis (3)
Nightmare (3)
Vomiting (3)
Eosinophilia (3)
Blood Urea Increased (2)
Asthenia (2)
Arthralgia (2)
Hallucination (2)
Haemorrhage (2)
Dizziness (2)
Conjunctivitis (2)
Bone Cancer Metastatic (2)
Anxiety (2)
Subdural Haematoma (2)
Pruritus (2)
Abdominal Pain Lower (2)
Tendon Rupture (2)
Neutropenia (2)
Lethargy (2)
Thrombocytopenia (2)
Leukocytosis (2)
Vitamin B12 Deficiency (2)
Pulmonary Embolism (1)
Lesion Excision (1)
Pulmonary Oedema (1)
Jaundice (1)
Urinary Tract Infection (1)
Liver Function Test Abnormal (1)
Ulcer Haemorrhage (1)
Vasculitis (1)
Presyncope (1)
Pericardial Effusion (1)
Oesophageal Haemorrhage (1)
Oedema (1)
Prostate Cancer (1)
Myocardial Infarction (1)
Malignant Melanoma (1)
Mucous Membrane Disorder (1)
Malaise (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After a urinalisis the doctor told me there were no white blood cells, only red blood cells in urine. drew blood and had cat scan and revealed a 7mm kidney stone. but i'm worried about having no white blood cell count in my urine

AFTER MY FIRST 2 PREGNANCY I HAD MINI STROKES SO HAD HEART OPP TO CLOSE HOLE IN MY HEART DUE TO LITTLE CLOT SHOOTING UP TO MY BRAIN WHILE I WAS PREGNANT. MY YOUGEST NOW IS 6 AND NOW PREGNANT WITH A NOTHER ONE . I WAKE UP DURING EARLY HOURS IN THE MOR

After surgery I was unable to urinate because of blood clots, had to wear a catheter for several days and then had to have it reinsereted for a brief period of time. After about a month my flow all but stopped. After examination w

Blood test really bruised arm getting worse very painfull

Check blood pressure and for female patients may be fibroids in uterus is the reason

Continuous headaches,cramp in legs at night after one weekof medication.

Daughter, at the age of 13, had first HPV Vaccine in June of this year (2011) Soon after she fell ill and was very pale, with heavier periods and tingling and numbness into her extremities and around her jaw and ears. We thought she had the flu, b

Going to be blund! After the family having vomiting and diarrhea coming out both ends(at the same time). 2 of us are left with diarrhea yet. Any LITTLE sip of water, 7up, gatorade, pedialyte, etc running right thru to the squirts. The only way to not

Have notified other sites did not know this site existed.Was on asasantin and having side effects like I was out of breath but wasn`t, don`t know what name is. but couldn`t associate with the list of known side effects. As time we

Hi!i am a doctor.i injected in deltoid 2cc gentamycin.skin swoll up..it was a new experienc..was injection given not deep enough by me?

I've been taking Coversyl for almost two weeks now. My doctor prescribed it when the Natrilix I had been taking for a couple of months wasn't bringing my blood pressure down fast enough. The only side effects I've noticed since commencing the C

Does panadeine increase blood pressure?

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Since taking Karvezide (2years after Karvea was proved to unsuccessfull in reducing my high blood pressusre) I have experienced a lot of problems with nasal drip and a permanent muscas build up in the throat. Nothing seems to relieve the problem.

When I reported to my doctor that i was frequently having to urinate he had a blood test carried out with the result that my prostrate was OK he prescribed Permixon 160 mg twice per day and Tamsulosina STADA 0,4 mg once per day. I am now urinating

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

I have an ear infection where my ear canal is covered in blisters and blood/fluid coming out, also mu ear is completely blocked. I am on antibiotics and drops but a friend mentioned that they took oflocet 200mg when had a similar problem, but I hav

Impact of this drug on blood pressure. Should I be worried?

sore kidneys/ inflamation of kidneys/ blood in urine

Blood Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Assessment of Blood Loss With a Point Of Care Device
Condition: Acute or Programmed Hip Replacement (Gamma Nail, Total Prosthesis or Throuhg DHS) / Knee Surgery
Intervention:
Outcome Measures: Perioperative Blood loss in mL assessed by NADLER & Mercurial formula* and PRU**/ARU*** as measured using the VerifyNow®P2Y12 and aspirin assays at baseline;   Evaluate the correlation between clopidogrel genetic metabolizer status**** and perioperative Blood loss.;   To evaluate clopidogrel and aspirin pharmacodynamic response at discharge according to metabolizer status.
2 Recruiting Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: ex vivo-expanded cord Blood progenitor cell infusion;   Procedure: umbilical cord Blood transplantation;   Procedure: double-unit umbilical cord Blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
Outcome Measures: Time to engraftment (ANC greater than or equal to 500) in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord Blood progenitors);   Time to engraftment, defined as the first of 2 consecutive days in which ANC is at least 500;   Relative contribution to engraftment of the expanded cord Blood product and the unmanipulated cord Blood unit(s) in early and long-term engraftment, determined by frequent determination of donor chimerism in the peripheral Blood;   Time to ANC greater than or equal to 100;   Time to ANC greater than or equal to 500;   Time to platelet engraftment (20k and 50k);   Duration of initial hospitalization;   Incidence of infectious complications;   Non-relapse mortality (NRM);   Incidence and severity of acute and chronic GVHD;   Infusional toxicity greater than or equal to grade 3;   Graft failure (primary and secondary);   Kinetics of immune system recovery as measured by T and B cell subsets, T cell receptor excision circles (TREC), spectratyping and T cell receptor (TCR) sequencing;   Death without engraftment
3 Recruiting Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion
Conditions: Blood Platelet Transfusion;   Blood Clotting
Intervention: Drug: Administration of platelet concentrate and taking Blood samples
Outcome Measures: difference in A30 (ExTEM®) between Blood samples after in vitro spiking and compared to those Blood samples obtained from the same patients after platelet transfusion;   Assessment of the difference in the response profile of Blood cell count (EDTA Blood sample);   Standard coagulation tests as aPTT, PT, fibrinogen and FXIII;   Further bleeding management system(ROTEM®)parameters
4 Recruiting New York Blood Center National Cord Blood Program
Conditions: Leukemia;   Lymphoma;   Genetic Disease;   Severe Aplastic Anemia;   Myelodysplasia
Intervention: Biological: Umbilical Cord Blood Transplantation
Outcome Measures: Engraftment;   Treatment Related Mortality;   Survival;   Graft vs. Host Disease;   Relapse
5 Recruiting Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw
Condition: Blood Loss
Intervention: Device: CM1500
Outcome Measure: Detect change in Blood volume by non-invasive monitoring during whole Blood draw
6 Recruiting Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis
Condition: Healthy
Intervention: Drug: Acetylcholine and Blood
Outcome Measures: Blood flow response to Acetylcholine.;   Change in Blood flow response to fresh Blood (5-10 days) in comparison to aged Blood.;   Comparison in the levels of various biomarkers of aged Blood will be examined in venous Blood collected from the antecubital vein during the infusion of 5-10 days versus35-42 days old autologous Blood.
7 Recruiting Improving Blood Safety and HIV Testing in Brazil
Conditions: HIV;   Herpes Simplex 2;   Hepatitis C;   Hepatitis B;   Chagas Disease
Interventions: Behavioral: HIV Counseling and Testing;   Behavioral: Blood Donation
Outcome Measures: HSV-2 Prevalence in Blood Donors;   Intervention Impact in Blood Donors;   Prevalence of Transfusion-Transmitted Infections in Blood Donors
8 Recruiting The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study
Conditions: Coronary Artery Disease;   Valvular Heart Disease
Interventions: Other: All-Blood cardioplegia;   Procedure: Standard cardioplegia
Outcome Measures: Blood transfusion;   Intra-op diastolic function;   Mortality;   Duration of Ventilation;   Lentgh of stay ICU;   Length of stay - hospital;   Other Blood product administration;   Hgb - arrival ICU;   Hgb - prior to Discharge;   Lowest post op Hgb;   Volume of crystalloid delivered in cardioplegia;   Fluid balance;   Reoperation rate for bleeding;   Inotrope score;   Low output syndrome;   Troponin;   Infection;   intra-op Ventricular function
9 Recruiting Cord Blood Fucosylation
Conditions: Blood And Marrow Transplantation;   Leukemia;   Lymphoma;   Transplantation Infection;   Transplantation, Bone Marrow
Interventions: Drug: Melphalan;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Procedure: Cord Blood Infusion;   Drug: Rituximab;   Drug: ATG;   Drug: Busulfan;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI)
Outcome Measures: Number of Participants with engraftment within 42 days;   Mean Time to Engraftment
10 Recruiting Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw
Condition: Blood Loss
Intervention: Device: CM 1500
Outcome Measures: Detect by non-invasive monitoring a change in Blood volume during a whole Blood draw;   Safety to determine non-serious unanticipated adverse device events (UADEs)
11 Unknown  Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans
Conditions: Glaucoma;   Ocular Physiology;   Regional Blood Flow
Interventions: Drug: Timolol (drug);   Drug: dorzolamide (drug);   Drug: brimonidine (drug);   Device: Laser Doppler flowmetry;   Device: Goldmann applanation tonometer;   Procedure: Suction cup method
Outcome Measures: Ocular perfusion pressure - ONH Blood flow relationship;   Blood pressure, heart rate
12 Recruiting Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
Condition: Infusion Reactions
Intervention: Drug: unlicensed cord Blood units
Outcome Measures: Incidence of infusion-related reactions of the unlicensed, investigational cord Blood units;   Incidence of transmission of infections after unrelated transplantation with investigational cord Blood units
13 Recruiting Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Condition: Whole Blood Donation and Leukoreduction
Intervention: Drug: SOLX
Outcome Measures: Red Blood Cell post-filtration recovery following > 6 hours at room temperature storage (Control);   Post-filtration residual leukocyte count after 6 hours of room temperature storage (Control);   Post-storage hemolysis;   Red Blood cell recovery;   Red Blood Cell post-filtration recovery following > 20 hours at room temperature storage (Test);   Red Blood Cell post-filtration recovery following > 66 hours refrigerated storage (Test and Control);   Post-filtration residual leukocyte count after 20 hours of room temperature storage (Test);   Post-filtration residual leukocyte count after 66 hours of refrigerated storage (Test and Control);   Plasma clotting factors levels;   Post-rejuvenation 2,3-DPG levels
14 Unknown  Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Conditions: Hematological Malignancy;   Bone Marrow Failure Syndrome
Interventions: Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders;   Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders;   Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Outcome Measures: To determine the safety and efficacy of multiple cord Blood transplantation in patients with hematological malignancy.;   To determine the 100-day treatment related mortality (TRM), complete remission rate and the 2-year progression free and overall survival rate for patients under going this treatment.;   To determine the incidence of grades II-IV and grades III-IV acute GVHD and incidence of limited and extensive chronic GVHD.;   To measure time to immunologic reconstitution as defined by normal numbers of T and B-cells and normal immunoglobulin synthesis;   To determine rate of hematologic engraftment following umbilical cord Blood transplantation with 1-2 cord Blood units using total body irradiation & fludarabine as transplant conditioning regimen & cyclosporine/MMF as graft-vs-host disease prophylaxis
15 Recruiting Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight (VLBW) Preterm Neonates: A Multi-center Randomized Clinical Trial
Condition: Anemia
Interventions: Procedure: Drawing admission labs from cord Blood;   Procedure: Drawing admission labs from infant Blood
Outcome Measures: Absolute hemoglobin concentration;   Percent change in hemoglobin concentration from baseline;   Number/volume of packed red Blood cell (pRBC) transfusions;   Number of Blood donor exposures;   Use of Vasopressors;   Hemoglobin concentration at one week of life;   Hemoglobin concentration at time of hospital discharge;   Head Ultrasound
16 Recruiting Autologous Umbilical Cord Blood Transfusion for Preterm Neonates
Conditions: Prematurity;   Respiratory Distress Syndrome;   Anemia of Prematurity;   Intraventricular Hemorrhage
Interventions: Biological: Autologous cord Blood transfusion for preterm neonates;   Biological: Autologous cord Blood transfusion
Outcome Measures: Duration of mechanical ventilation;   Survival
17 Recruiting Safety Study of Cord Blood Units for Stem Cell Transplants
Conditions: Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
Intervention: Procedure: Cord Blood Units
Outcome Measure: Examine the safety of administration of the unlicensed investigational NCBP HPC-CORD Blood products
18 Recruiting INTERVAL Study: To Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased
Condition: Blood Donation
Intervention: Other: Reduced versus standard intervals between Blood donations
Outcome Measures: Total Blood collected after two years;   Donor quality of life;   Number of donation deferrals;   Markers of iron status;   Cognitive ability;   Levels of physical activity;   Cost effectiveness;   Donor attitudes, beliefs and values
19 Recruiting Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial
Condition: Transfusion, Age of Blood.
Intervention: Other: Blood transfusion
Outcome Measures: Mortality;   Persistent Organ Dysfunction combined with death;   Days alive and free of mechanical ventilation;   Day alive and free of renal replacement therapy.
20 Recruiting Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord Blood transplantation;   Radiation: total-body irradiation;   Other: laboratory biomarker analysis
Outcome Measures: Overall survival;   Incidence of non-relapse mortality;   Incidence of graft failure/rejection;   Incidence of neutrophil engraftment;   Incidence of platelet engraftment;   Incidence of grade II-IV and III-IV acute GVHD for each arm;   Incidence of chronic GVHD for each arm;   Incidence of relapse or disease progression;   Progression-free survival;   Incidence of clinically significant infections